CCND1 and prostate carcinoma: This supports the utility of nano-formulations in enhancing anti-cancer efficacy, consistent with findings by Syrovets, Gschwend [55], who showed boswellic acid derivatives downregulating cyclin D1 in prostate cancer cells.